EKF Diagnostics Holdings plc
("EKF" or "the Company")
Notice of Interim Results
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care diagnostics business, will announce its interim results for the 6 month period ended 30 June 2011 on Wednesday 28 September 2011.
The management team will be hosting analyst and media briefings on the day. For more information please contact Walbrook PR Ltd.
|
Walbrook PR Limited |
Tel: 020 7933 8780 |
|
Fiona Henson |
Mob: 07886 335 992 or fiona.henson@walbrookpr.com |
|
Paul McManus |
Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com |
About EKF Diagnostics Holdings plc
EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US$25.5m).
The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.
In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo_Control device and cuvettes in the US, Canada and United Kingdom.
For more information please visit the website: www.ekfdiagnostics.co.uk